全文获取类型
收费全文 | 3633篇 |
免费 | 211篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 122篇 |
妇产科学 | 64篇 |
基础医学 | 506篇 |
口腔科学 | 60篇 |
临床医学 | 310篇 |
内科学 | 1050篇 |
皮肤病学 | 46篇 |
神经病学 | 350篇 |
特种医学 | 96篇 |
外科学 | 324篇 |
综合类 | 7篇 |
预防医学 | 150篇 |
眼科学 | 11篇 |
药学 | 330篇 |
中国医学 | 24篇 |
肿瘤学 | 401篇 |
出版年
2023年 | 17篇 |
2022年 | 50篇 |
2021年 | 89篇 |
2020年 | 60篇 |
2019年 | 63篇 |
2018年 | 100篇 |
2017年 | 75篇 |
2016年 | 93篇 |
2015年 | 114篇 |
2014年 | 125篇 |
2013年 | 172篇 |
2012年 | 267篇 |
2011年 | 274篇 |
2010年 | 135篇 |
2009年 | 171篇 |
2008年 | 258篇 |
2007年 | 238篇 |
2006年 | 211篇 |
2005年 | 223篇 |
2004年 | 218篇 |
2003年 | 184篇 |
2002年 | 178篇 |
2001年 | 45篇 |
2000年 | 58篇 |
1999年 | 51篇 |
1998年 | 46篇 |
1997年 | 36篇 |
1996年 | 30篇 |
1995年 | 17篇 |
1994年 | 9篇 |
1993年 | 15篇 |
1992年 | 33篇 |
1991年 | 24篇 |
1990年 | 31篇 |
1989年 | 20篇 |
1988年 | 23篇 |
1987年 | 11篇 |
1986年 | 6篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 12篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1976年 | 3篇 |
1973年 | 4篇 |
1967年 | 3篇 |
1943年 | 4篇 |
1941年 | 3篇 |
排序方式: 共有3872条查询结果,搜索用时 93 毫秒
101.
Novo G Rizzo M La Carruba S Caruso M Amoroso GR Balistreri CR Coppola G Evola G Caruso C Assennato P Novo S Mancuso D 《Angiology》2012,63(2):127-130
We assessed whether macrophage colony-stimulating factor (M-CSF) levels are associated with left ventricular systolic dysfunction (LVSD) in patients with acute myocardial infarction (AMI). We studied 56 patients with AMI (mean age: 67 ± 12 years) and identified those with clinical (Killip class >II) or echocardiographic signs (ejection fraction ≤45%) of LVSD. We evaluated the established cardiovascular risk factors and measured several cardiovascular biomarkers, including M-CSF. Serum M-CSF concentrations (pg/mL) were significantly increased in patients with both clinical and echocardiographic signs of LVSD (460 ± 265 vs 290 ± 210, P = .0103 and 493 ± 299 vs 287 ± 174, P = .0028, respectively). We found a significant inverse association between M-CSF and ejection fraction (r = -.351, P = .0079). Logistic regression analysis revealed that, among all evaluated clinical and biochemical parameters, the stronger predictor of LVSD was M-CSF (odds ratios 2.1, 95% confidence interval 1.1-2.9, P = .0168). This is the first study reporting plasma M-CSF levels as independent determinants of low LV ejection fraction and clinical LV dysfunction in patients with AMI. 相似文献
102.
103.
Breccia M Mazzarella L Bagnardi V Disalvatore D Loglisci G Cimino G Testi AM Avvisati G Petti MC Minotti C Latagliata R Foà R Pelicci PG Lo-Coco F 《Blood》2012,119(1):49-54
We investigated whether body mass index (BMI) correlates with distinct outcomes in newly diagnosed acute promyelocytic leukemia (APL). The study population included 144 patients with newly diagnosed and genetically confirmed APL consecutively treated at a single institution. All patients received All-trans retinoic acid and idarubicin according to the GIMEMA protocols AIDA-0493 and AIDA-2000. Outcome estimates according to the BMI were carried out together with multivariable analysis for the risk of relapse and differentiation syndrome. Fifty-four (37.5%) were under/normal weight (BMI < 25), whereas 90 (62.5%) patients were overweight/obese (BMI ≥ 25). An increased BMI was associated with older age (P < .0001) and male sex (P = .02). BMI was the most powerful predictor of differentiation syndrome in multivariable analysis (odds ratio = 7.24; 95% CI, 1.50-34; P = .014). After a median follow-up of 6 years, the estimated cumulative incidence of relapse at 5 years was 31.6% (95% CI, 22.7%-43.8%) in overweight/obese and 11.2% (95% CI, 5.3%-23.8%) in underweight/normal weight patients (P = .029). Multivariable analysis showed that BMI was an independent predictor of relapse (hazard ratio = 2.45, 95% CI, 1.00-5.99, in overweight/obese vs under/normal weight patients, P = .049). An increased BMI at diagnosis is associated with a higher risk of developing differentiation syndrome and disease relapse in APL patients treated with AIDA protocols. 相似文献
104.
105.
Maggio A Vitrano A Lucania G Capra M Cuccia L Gagliardotto F Pitrolo L Prossomariti L Filosa A Caruso V Gerardi C Campisi S Cianciulli P Rizzo M D'Ascola G Ciancio A Di Maggio R Calvaruso G Pantalone GR Rigano P 《American journal of hematology》2012,87(7):732-733
A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1]. 相似文献
106.
107.
108.
109.
Werner Lukas Pabst Thomas J. Neuhaus Samuel Nef Elena Bresin Andrea Zingg-Schenk Giuseppina Spartà 《Pediatric nephrology (Berlin, Germany)》2013,28(7):1141-1144
Background
Atypical haemolytic uremic syndrome (aHUS) is often associated with a high risk of disease recurrence and subsequent graft loss after isolated renal transplantation. Evidence-based recommendations for a mutation-based management after renal transplantation in aHUS caused by a combined mutation with complement factor I (CFI) and membrane cofactor protein CD46 (MCP) are limited.Case-diagnosis/Treatment
We describe a 9-year-old boy with a first manifestation of aHUS at the age of 9 months carrying combined heterozygous mutations in the CFI and MCP genes. At the age of 5 years, he underwent isolated cadaveric renal transplantation. Fresh frozen plasma was administered during and after transplantation, tapered and finally stopped after 3 years.Conclusions
During the 5-year follow-up after transplantation there have been no signs of aHUS recurrence and graft function has remained good. The combination of heterozygous MCP and CFI mutations with aHUS might have a positive impact on the post-transplant course, possibly predicting a lower risk of aHUS recurrence after an isolated cadaveric renal transplantation 相似文献110.
Francesca Nolfo Stefania Rametta Stefano Marventano Giuseppe Grosso Antonio Mistretta Filippo Drago Santi Gangi Francesco Basile Antonio Biondi 《BMC surgery》2013,13(Z2):S16